期刊文献+

他达拉非半量隔日口服治疗ED的疗效观察 被引量:10

Clinical efficiency of interval day oral half dose of tadalafil on treatment of ED
下载PDF
导出
摘要 目的:评估他达拉非半量(10 mg)隔日口服治疗勃起功能障碍(ED)的疗效。方法:选择158例符合美国国立卫生研究院诊断标准的ED患者,随机分为他达拉非(希爱力)组和复方玄驹胶囊组两组,分别接受3个月的治疗,治疗后各组又随访3个月以上。采用勃起功能障碍症状评分(international index of erectilefunction-5,IIEF-5)评估治疗前后及继续随访3个月后各组的疗效,同时比较患者性生活日记中插入成功率和性交中保持勃起至完成性交的成功率。采用焦虑自评量表评价焦虑状态。结果:治疗前两组IIEF-5评分分别为(9.96±4.21)、(9.69±4.35)分,差异无统计学意义(P>0.05)。治疗3个月后IIEF-5评分分别为(20.38±4.18)、(16.08±3.26)分,随访至6个月时IIEF-5评分分别为(18.16±2.31)、(11.98±3.97)分,差异均有统计学意义(P<0.01),而且两组间在治疗后和6个月随访时的评分差异也具有统计学意义(P<0.05)。药物治疗后,患者性生活日记中插入成功率和保持勃起的成功率明显提高,希爱力组高于复方玄驹胶囊组。焦虑评分值两组治疗后明显低于治疗前(P<0.05)。结论:他达拉非隔日半量口服可有效治疗ED,且疗效优于传统中药,可作为临床上的一线治疗方法。 Objective:To evaluate the clinical efficiency of interval day oral half dose of tadalafil on treatment of erectile dysfunction(ED).Methods:Total of 158 cases ED patients were divided into 2 groups randomly including tadalafil(cialis) group and FuFangXuanJu Capsule group.International index of erectile function-5(IIEF-5) scores of patients in each group were recorded and compared before and after 3-months treatment and 3-months discontinuing the drug and the satisfaction degree of coitus in patients diary and anxiety symptoms(SAS score) of all patients were also comparatively analyzed.Results:Before treatment,the IIEF-5 scores of two groups were 9.96±4.21 and 9.69±4.35 respectively and no significant difference was found between two groups(P0.05).After treatment,the IIEF-5 scores were 20.38±4.18 and 16.08±3.26 respectively,and 3-months after discontinuing the drug,the IIEF-5 scores were 18.16±2.31 and 11.98±3.97 respectively.There were significant differences between pre-treatment and post-treatment(P0.01).A significant difference in IIEF-5 scores was also found in two groups post treatment and 3-months after discontinuing the drug(P0.05).Tadalafil was shown to be better in improving satisfaction degree of coitus and SAS score of two groups after treatment was significantly lower than that of pre-treatment(P0.05).Conclusion:For treatment of ED,clinical efficiency of interval day oral half dose of tadalafil is superior to that FuFangXuanJu Capsule and should be recommended to be a better option in therapy of ED.
出处 《东南大学学报(医学版)》 CAS 2012年第2期183-186,共4页 Journal of Southeast University(Medical Science Edition)
关键词 勃起功能障碍 他达拉非 5型磷酸二酯酶抑制剂 erectile dysfunction tadalafil phosphodiesterase 5 inhibitors
  • 相关文献

参考文献4

二级参考文献35

  • 1王忠,袁国英,张继贵,周晓春,欧阳军,刘保钢,王振国,谷顺才.复方玄驹口服液补肾壮阳药效学研究[J].中药新药与临床药理,1996,7(2):51-53. 被引量:55
  • 2Litwin SM,McNaughton-Collins M,Fowler FJ,et al.The NIH Chronic Prostatitis Symptom Index(NIH-CPSI):Development and validation of a new outcomes measure [ J ].J Urol,1999,162(4):369-375.
  • 3Liang CZ,Zhang XJ,Hao ZY,et al.Prevalence of sexual dysfunction in Chinese men with chronic prostatitis [ J].BJU Int,2004,93(4):568-570.
  • 4Uckert S,Kuthe A,Jonas U,et al.Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human protate[J].J Urol,2001,166(6):2484-2490.
  • 5Rosen RC,Riley A,Wagner G,et al.The International Index of Erectile Function(IIEF):a multidimensional scale for assessment of erectile dysfunction [ J ].Urology,1997,49(6):822-830.
  • 6Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84(1): 50-56
  • 7NIH Consensus Conference Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270(1): 83-90
  • 8Wespes E, Amar E, Hatzichristou DG, et al. Guidelines on erectile dysfunction. Eur Urol 2002; 41(1): 1-5
  • 9Rosen RC, FisherWA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20(5): 607-617
  • 10S a nchez-Cruz JJ, Cabrera-Lean A, Martin-Morales A, et al. Male erectile dysfunction and health-related quality of life. Eur Urol 2003; 44 (2): 245-253

共引文献46

同被引文献125

  • 1朱华,须媚.勃起功能障碍治疗药 他达那非(tadalafil)[J].世界临床药物,2004,25(9):572-572. 被引量:4
  • 2张春梅,冯霞,钟艺.蛇床子的药理研究进展[J].实用药物与临床,2006,9(1):55-57. 被引量:61
  • 3Vassilis Poulakis,Konstantinos Skriapas,Rachelle de Vries,Wolfgang Dillenburg,Nikolaos Ferakis,Ulrich Witzsch,Michael Melekos,Edward Becht.Extracorporeal shockwave therapy for Peyronie's disease: an alternative treatment?[J].Asian Journal of Andrology,2006,8(3):361-366. 被引量:5
  • 4吴福星,李郑林,朱美艳.蚂蚁的应用研究现状及进展[J].云南中医中药杂志,2006,27(4):59-60. 被引量:11
  • 5Fusco F, Razzoli E, hnbimbo C, et al. A new era in the treatment of erectile dysfunction : chronic phosphodiesterase type 5 inhibition [J].BJU Int,2010, 105 ( 12 ) : 1634 - 1639.
  • 6Leo CH, Hart JL, Woodman OL. Impairment of both nitric oxide- mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes [ J ]. Br J Pharma- col,2011,162(2) :365 -377.
  • 7Gonzalez-Corrochano R, La Fuente J, Cuevas P, et al. Ca^2+ -activa- ted K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in hmnan penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction [ J ]. Br J Pharmacol,2013,169 ( 2 ) :449 - 461.
  • 8Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 rag and 10 mg in the treatment of erectile dysfunction : Results of amulticenter, randonized,double-blind,placebo controlled trial[ J]. Eur Urol,2006,50 (2) :351 -359.
  • 9Lee JW, Park HJ,Park NC. Serum high-sensitivity C-reactive pro- rein levels and response to 5 mg tadalafil Once daily in patients with erectile dysfunction and diabetes[ J ]. Korean J Urol,2013,54 (12) :858 -864.
  • 10Lee CH,Kim HS, Coo M J, et al. Chronic administration of udena- fil,a selective phosphodiesterase type 5 inhibitor,promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury [ J ]. J Sex Med,2011, 8 ( 5 ) : 1330 - 1340.

引证文献10

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部